CRMD stock forecast
Our latest prediction for CorMedix, Inc.'s stock price was made on the Sept. 30, 2019 when the stock price was at 6.38$.
In the short term (2weeks), CRMD's stock price should outperform the market by 1.62%. During that period the price should oscillate between -8.93% and +13.52%.
In the medium term (3months), CRMD's stock price should underperform the market by -2.48%. During that period the price should oscillate between -22.82% and +36.05%.Get email alerts
About CorMedix, Inc.
CorMedix, Inc. operates as a pharmaceutical and medical device company, which seeks to in-license, develop and commercialize prophylactic and therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The firm is developing its product Neutrolin, a novel, non-antibiotic antimicrobial solution designed to prevent costly and dangerous bloodstream infections associated with the use of central venous catheters. The company was founded by Antony E. Pfaffle in 2006 and is headquartered in Berkeley Heights, NJ.
At the moment the company doesn't generate any revenue.
On its last earning announcement, the company reported a loss of -1.39$ per share.
The book value per share is -0.07$
Three months stock forecastSept. 30, 2019
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|